PolyMedix, Inc. (PYMX.OB) Secures $14 Million Credit Facility and Files Shelf Registration Statement
PolyMedix Inc. is a biotechnology company focused on the development of new therapeutic drugs for the treatment of acute cardiovascular disorders and infectious diseases. The company's compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. The company announced today that it has secured a $14 million credit facility with Hercules Technology II L.P. Hercules Technology is an affiliate of Hercules Technology Growth Capital Inc. (NASDAQ: HTGC), a specialty finance company providing debt and equity growth capital to technology and life science companies at all stages of development. PloyMedix expects that the…